CAR-T in 2025: Advancements and the Road Ahead

Jason Westin, M.D., MS, FACP, MD Anderson Cancer Center, Houston, TX

Recorded on January 21, 2025

Jason Westin, M.D., MS, FACP
Professor, Department of Lymphoma & Myeloma
Lead, Lymphoma & Myeloma Service Line
Director, Lymphoma Clinical Research
Section Chief, Aggressive and Indolent Lymphoma
MD Anderson Cancer Center
Houston, TX

In this episode, Dr. Jason Westin from MD Anderson Cancer Center in Houston, Texas explores CAR T-cell therapy, covering both current and emerging indications. He highlights the educational needs of patients and caregivers, as well as the essential role of community and academic collaboration before and after treatment. Dr. Westin also discusses the use of minimal/measurable residual disease (MRD) in treatment planning, future directions of CAR-T, and ongoing clinical trials. Tune in to stay up-to-date on the latest advancements in CAR T-cell therapy!

This episode is supported by Allogene Therapeutics, Bristol Myers Squibb, Johnson
& Johnson & Legend Biotech, and Kite, a Gilead Company.